Compare Novo Nordisk A/S (NVO) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Toyota Motor Corp — how do they compare? Novo Nordisk A/S trades at $49.39 (market cap $220.53B), while Toyota Motor Corp trades at $179.51 (market cap $212.22B). The key difference: Novo Nordisk A/S and Toyota Motor Corp are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | TM | |
|---|---|---|
Market Cap | $220.53B | $212.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $248.29 |
52-Week Low | $35.29 | $166.50 |
Enterprise Value | $239.49B | $376.42B |
Dividend Yield | 3.63% | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Toyota Motor (TM) trades at $180.34, up 1.54% today, showing strong fundamental metrics with a P/E of 9.78 and consistent earnings beats. Technical indicators are neutral overall, with the stock near resistance at $182. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic US investment.
The outlook is positive given undervaluation signals and hybrid vehicle leadership, but risks include margin pressure from rising costs and competitive auto market dynamics. Analyst consensus is mixed with 37.5% buy ratings, suggesting cautious optimism amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
